Iktos
Victoire M. L. Cachoux, PhD, has a diverse work experience. Victoire M. L. started their career as a research intern at the Institut Curie - Research Centre in 2016, where they conducted a study on the biophysical parameters driving cell delamination during drosophila morphogenesis. Victoire M. L. received a research prize for their work.
In 2017, they joined Nest For All as a Quality Engineer and Project Manager. Victoire M. L. contributed to the certification for ISO 9001 Quality Management by reviewing and updating the processes to ensure the quality of their services.
In 2018, Victoire began their PhD at the Institut Curie - Research Centre. Their project focused on understanding the biophysical regulation of cell death in the development of epithelial tissues. Victoire M. L. successfully defended their PhD in July 2022.
During their PhD, they also took on the role of Vice-President at Low Carbon France from March 2018 to January 2022, where they were involved in environmental initiatives.
In 2019, they became an Oral Examiner in Mathematics at Lycée Saint Louis, a position they held until June 2022.
Starting in October 2022, Victoire will be taking on the role of Application Scientist Asia at Iktos.
Victoire M. L. Cachoux, PhD, pursued their education in engineering. From 2013 to 2016, they attended École Polytechnique, where they completed their Diplôme d'ingénieur. Subsequently, from 2016 to 2017, Victoire continued their studies at the University of Cambridge, obtaining a Master of Philosophy (MPhil) degree in Engineering.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.